Previous Close | 14.25 |
Open | 14.38 |
Bid | 13.01 x 100 |
Ask | 13.05 x 100 |
Day's Range | 12.99 - 14.68 |
52 Week Range | 10.93 - 28.99 |
Volume | |
Avg. Volume | 899,088 |
Market Cap | 817.862M |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.31 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 38.27 |
WALTHAM, Mass., April 04, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company’s common stock to th
WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
Viridian Therapeutics ( NASDAQ:VRDN ) Full Year 2023 Results Key Financial Results Net loss: US$237.7m (loss widened by...